Taking into account that previous studies showed alterations of NK cell functionality in myeloid malignancies (39) and limited clinical activity of ADCC competent antibodies against other targets (e.g. CD33, CD123) (40–42), investigating the cytotoxic potential of autologous patient derived NK cells would be of high interest. Here, CD33 is linked to myeloid neoplasm.